WO2008087170A3 - Gènes associés à la schizophrénie - Google Patents

Gènes associés à la schizophrénie Download PDF

Info

Publication number
WO2008087170A3
WO2008087170A3 PCT/EP2008/050477 EP2008050477W WO2008087170A3 WO 2008087170 A3 WO2008087170 A3 WO 2008087170A3 EP 2008050477 W EP2008050477 W EP 2008050477W WO 2008087170 A3 WO2008087170 A3 WO 2008087170A3
Authority
WO
WIPO (PCT)
Prior art keywords
schizophrenia
genes associated
sp0ck1
p0lr1a
mgc33657
Prior art date
Application number
PCT/EP2008/050477
Other languages
English (en)
Other versions
WO2008087170A2 (fr
Inventor
Pierandrea Muglia
Original Assignee
Glaxo Group Ltd
Pierandrea Muglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Pierandrea Muglia filed Critical Glaxo Group Ltd
Publication of WO2008087170A2 publication Critical patent/WO2008087170A2/fr
Publication of WO2008087170A3 publication Critical patent/WO2008087170A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/302—Schizophrenia

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un procédé de criblage d'un composé à petites molécules destiné au traitement de la schizophrénie, lequel procédé consiste à déterminer si le composé d'essai précité possède une affinité contre une cible choisie dans le groupe constitué des produits géniques codés par: CTNNA2, LRRTM1, DPP10; IL1 RN; DBI; RANBP2L1; ACOXL; CCDC93; CNTNAP5; CXCR4; PTCD3; FLJ42986; IL1 F10; IL1 F5; LOC200383; MGC33657; MGC4677; P0LR1A; PTPN4; SLC9A2 SUCLG1; TFCP2L1; ZC3H6; FBXL21; JMJD1 B; SP0CK1; HTR4; ITK; LOC345537; MEGF10; et PRDM6.
PCT/EP2008/050477 2007-01-19 2008-01-17 Gènes associés à la schizophrénie WO2008087170A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0701096A GB0701096D0 (en) 2007-01-19 2007-01-19 Use
GB0701096.0 2007-01-19

Publications (2)

Publication Number Publication Date
WO2008087170A2 WO2008087170A2 (fr) 2008-07-24
WO2008087170A3 true WO2008087170A3 (fr) 2008-12-11

Family

ID=37846679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050477 WO2008087170A2 (fr) 2007-01-19 2008-01-17 Gènes associés à la schizophrénie

Country Status (2)

Country Link
GB (1) GB0701096D0 (fr)
WO (1) WO2008087170A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108410867A (zh) * 2018-02-13 2018-08-17 广州市番禺区中心医院(广州市番禺区人民医院、广州市番禺区心血管疾病研究所) 一种新的抑郁症的标记物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055813A2 (fr) * 2003-12-08 2005-06-23 Agy Therapeutics, Inc. Interaction du recepteur nmda avec la proteine tyrosine phosphatase step dans des troubles psychotiques
WO2006105516A2 (fr) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005055813A2 (fr) * 2003-12-08 2005-06-23 Agy Therapeutics, Inc. Interaction du recepteur nmda avec la proteine tyrosine phosphatase step dans des troubles psychotiques
WO2006105516A2 (fr) * 2005-03-31 2006-10-05 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques

Also Published As

Publication number Publication date
GB0701096D0 (en) 2007-02-28
WO2008087170A2 (fr) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2010088411A3 (fr) Peptides dynamiques par conformation
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
MX277232B (es) Recubrimiento grueso de piso teniendo propiedades antiestaticas.
WO2009129505A3 (fr) Compositions, procédé et trousses utilisant des sondes synthétiques pour déterminer la présence d'un acide nucléique voulu
ZA200810780B (en) Non-destructive testing, in particular for pipes during manufacture or in the finished state
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2008061213A3 (fr) Variations génétiques associées à des tumeurs
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
WO2008022295A3 (fr) anticorps spécifiques du PRLR et leurs utilisations
ZA201004112B (en) Non-destructive testing,in particular for tubes during manufacture or in the finished state
WO2010009368A3 (fr) Compositions pour la détection et le traitement du cancer colorectal
WO2009058564A3 (fr) Polypeptide immunosuppresseur et acides nucléiques
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2008011519A3 (fr) Inhibiteurs d'amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2009140039A3 (fr) Anticorps synthétiques
EP2164991A4 (fr) Procédés, systèmes et kits pour évaluer une sclérose en plaques
WO2005116252A3 (fr) Procede d'evaluation de sequences de ribonucleotides
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2008089073A3 (fr) Banques combinatoires de séquences polypeptidiques conformationnellement contraintes
WO2009120183A3 (fr) Système pour la détection d’un pathogène biologique et utilisation de celui-ci
WO2008019326A3 (fr) Anticorps spécifique de ephb3 et ses utilisations
EP1828754A4 (fr) Systemes et procede d'examen de revetements, de surfaces et d'interfaces
WO2010032022A8 (fr) Utilisation d'un inhibiteur de la protéine kinase pour détecter des cellules immunes, tels que des lymphocytes t
WO2008070325A3 (fr) Variations génétiques associées à des tumeurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701539

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701539

Country of ref document: EP

Kind code of ref document: A2